London · Delayed Price · Currency is GBP · Price in USD Prothena Corporation Company Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies.
The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aβ-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.
It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 163 |
| CEO | Gene Kinney |
Contact Details
Address: 77 Sir John Rogerson’s Quay Dublin, D02 VK60 Ireland | |
| Phone | 353 1 236 2500 |
| Website | prothena.com |
Stock Details
| Ticker Symbol | 0Y3M |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gene Kinney | Chief Executive Officer |
| Tran Nguyen | Chief Financial Officer |
| Brandon Smith | Chief Operating Officer |
| Mark Johnson | Head of Investor Relations |